Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Apolipoprotein B(ApoB) Reduction by ISIS 301012 on Liver Triglyceride Content in Subjects With Varying Degrees of Hyperlipidemia
NCT00362180 is registered in ClinicalTrials.gov with Kastle Therapeutics, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Apolipoprotein B(ApoB) Reduction by ISIS 301012 on Liver Triglyceride Content in Subjects With Varying Degrees of Hyperlipidemia
- Lead sponsor
- Kastle Therapeutics, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2006
- Completion date
- September 30, 2010
- Enrollment
- 38 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
congenital abnormalities, dyslipidemias, genetic diseases, inborn, hypercholesterolemia, hyperlipidemias, hypobetalipoproteinemias, hypolipoproteinemia, hypolipoproteinemias, infant, newborn, diseases, lipid metabolism disorders, lipid metabolism, inborn errors, metabolic diseases, metabolic disorder, metabolism, inborn errors